SGK3 and obesity due to melanocortin 4 receptor deficiency: The marked metabolic benefits conferred by SGK3 inhibition under both DEX and HFD challenge establish it as a promising therapeutic target for glucocorticoid-induced and obesity-related metabolic disorders.